Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing of RNA from HDAC inhibitor and/or doxorubicin treated samples

ABSTRACT: Our study represents the first detailed analysis of transcriptomes in HDAC inhibitor and doxorubicin treated leukemic cells. The goal of this study is to identify gene expression patterns in HDAC and/or doxorubicin treated leukemic cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE86783 | GEO | 2021/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide nuclesome occupancy following HDAC inhbitor and/or doxorubicin treatment

Project description:The goal of this study is to identify nucleosome occupancies in leukemic cells treated with either HDAC inhibitor or doxorubicin or HDAC inhibitor plus doxorubicin

2021-07-01 | GSE86784 | GEO

Doxorubicin and protective inhibitor treated iPSC derived cardiomyocytes

Project description:Doxorubicin and protective inhibitor treated iPSC derived cardiomyocytes

| PRJNA880508 | ENA

Gene expression profiles of prostate cancer cell line with or without HDAC inihbitors

Project description:Histone deacetylase (HDAC) inibitors suppress cell proliferation of prostate cancer, but the detailed mechanisms are unknown. Moreover, HDAC includes 18 family members, namely HDAC1-11 and SIRT1-7, and differences of effects on prostate cancer proliferation among these enzymes are also unknown. Thus, we clarified differences of gene expression between prostate cancer cell line (LNCaP) treated with pan-HDAC inhibitors (TSA and OBP-801) or selective HDAC inhibitor (NCC-149, HDAC8-specific inhibitor)using cDNA microarray. LNCaP treated with TSA (1Î¼M), NCC149 (2Î¼M), OBP-801 (200nM) or DMSO for 24hrs, RNA was extracted from cells, and cDNA array was performed.

2015-11-04 | E-GEOD-74418 | biostudies-arrayexpress

Gene expression profiles of prostate cancer cell line with or without HDAC inihbitors

2015-11-04 | GSE74418 | GEO

HDAC Inhibitor Conjugated Polymeric Prodrug Micelles for Doxorubicin Delivery.

Project description:Amphiphilic diblock copolymers bearing histone deacetylase inhibitors (HDACi) (4-phenyl butyric acid and valproic acid) were synthesized by the ring-opening polymerization of γ-4-phenylbutyrate-ε-caprolactone (PBACL), γ-valproate-ε-caprolactone (VPACL), and ε-caprolactone (CL) from a poly(ethylene glycol) macroinitiator (PEG). These amphiphilic diblock copolymers self-assembled into stable pro-drug micelles and demonstrated excellent biocompatibility. High loading of doxorubicin (DOX) up to 5.1 wt% was achieved. Optimized micelles enabled sustained drug release in a concentration-dependent manner over time to expand the therapeutic window of cytotoxic small molecule drugs.

| S-EPMC5473365 | biostudies-literature

Analysis of genome maintenance in Philadelphia-positive leukemia following HDAC inhibition and doxorubicin treatment

Project description:Analysis of genome maintenance in Philadelphia-positive leukemia following HDAC inhibition and doxorubicin treatment

| PRJNA342491 | ENA

Mouse brain microarray, Chronic HDAC inhibitor treatment

Project description:Here, we examined mouse brain trancriptional changes 1 hour after the 10th daily i.p. treament with one of the four following treaments: i) vehicle control (45% saline, 45% PEG-400 and 10% DMSO administered at 7.5mL/kg), ii) Cpd-60, 45mg/kg , administered at 7.5mL/kg or iii) SAHA, 25mg/kg, administered at 5mL/kg) or iv) CI-994, 10mg/kg, administered at 5mL/kg. Cpd-60 is a benzamide HDAC inhibitor with selectivity for class I HDAC subtypes HDAC1 and HDAC2; CI-994 is a benzamide inhibitor with selectivity for HDACs1,2 and 3; SAHA is a hydroxamic acid HDAC inhibitor with selectivity for class I HDAC subtypes 1,2, and 3 and the class II HDAC subtype HDAC 6. We examined transcript differences using the Illumnia WG-6 2.0 whole genome expression array and profiled 3 specific brain regions (prefrontal cortex, nucleus accumbens, hippocampus) from each of 36 mice (n=6 mice / treatment group) . For application to array chips, we pooled two biological replicates from like treatment and brain region-groups such that 36 samples were applied in total: 4 treatment groups x 3 brain regions per treament group x 3 pools of two samples each for each treatment/brain region.

2013-05-29 | GSE47452 | GEO

Mouse embryonic kidneys (E13.5): HDAC inhibitor (HDACi) treated vs. Control

Project description:Transcriptional profiling of cultured CD1 mouse embryonic kidneys (E13.5) comparing HDACi-treated kidneys with control drug-treated kidneys. Studies in our lab showed that pharmacological inhibition of HDAC activity in ex-vivo cultured metanephroi results in extensive defects in kidney development, including impaired UB branching, tubulogenesis, and glomerulogenesis, accompanied by cell cycle arrest and apoptosis.The goal of the microarray analysis was to elucidate the morphogenetic pathways affected by HDACi.

2010-08-01 | GSE19581 | GEO

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed Q175 mice.

Project description:WT and Q175 heterozygous (het) mice treated orally twice a day with vehicle (10% HPβCD), and Q175 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 weeks to 6 months of age.

2017-09-23 | GSE104064 | GEO

Doxorubicin and protective inhibitor treated iPSC derived cardiomyocytes

Project description:Investigation of drug and gene rescues doxorubicin induced alterations of transcriptomic and metabolic profiles

2024-09-01 | GSE213311 | GEO